Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00927823 · ClinicalTrials.gov registry record · Phase 1

A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

A Phase 1 study of Cancer, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
37
Enrollment target
7
Study locations

NCT00927823 is a Phase 1 study of Cancer that has completed, run by Pfizer. The registered enrollment target is 37 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00927823, a Phase 1 study of Cancer, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
37 participants
Enrollment target
7
Study locations

Study Summary

A phase 1 dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of PF-04691502 in adult cancer patients with solid tumors.

Conditions Studied

Cancer

Interventions

  • DRUG PF-04691502

Study Locations (7)

California

  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Santa Monica

New York

  • Pfizer Investigational Site - Amherst
  • Pfizer Investigational Site - Buffalo

Michigan

  • Pfizer Investigational Site - Detroit

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2009-12
Est. Completion 2012-04
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00927823

The ClinicalTrials.gov registry entry for NCT00927823 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which PF-04691502 is the first listed.

NCT00927823 reports 7 study locations spanning 3 distinct geographic areas - top geographies include California, New York, Michigan.

Frequently Asked Questions

What is clinical trial NCT00927823 about?

NCT00927823 is a clinical study titled "A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients". A phase 1 dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of PF-04691502 in adult cancer patients with solid tumors.

What is the current status of trial NCT00927823?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2009-12. Estimated completion is 2012-04.

What conditions does trial NCT00927823 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT00927823?

The interventions under investigation include: PF-04691502 (DRUG).

Who is sponsoring clinical trial NCT00927823?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00927823 being conducted?

This trial has 7 study locations across California, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.